The current financial score of Celularity Inc is 6.62. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.10M, representing a year-over-year decrease of 77.37%, while its net profit experienced a year-over-year decrease of 83.90%.
The current valuation score of Celularity Inc is 8.74. Its current P/E ratio is -0.32, which is -3635.02% below the recent high of 11.34 and -888.62% above the recent low of -3.17.
No earnings forecast score is currently available for Celularity Inc. The Pharmaceuticals industry's average is 7.83. The average price target is 6.00, with a high of 6.00 and a low of 6.00.
The current price momentum score of Celularity Inc is 6.90. Currently, the stock price is trading between the resistance level at 2.21 and the support level at 0.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of Celularity Inc is 3.00. The latest institutional shareholding proportion is 12.95%, representing a quarter-over-quarter decrease of 5.62%.
The current risk assessment score of Celularity Inc is 1.41. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.